AHA 2021 As part of the ACTIV-4a study, it was examined whether use of P2Y12 inhibitors (ticagrelor or clopidogrel) changed the number of organ support-free days in a period of 28 days in non-critically ill hospitalized patients with COVID-19.

AHA 2021 Rafael Diaz explains the rationale and shares the results of the PREPARE-IT-2-study, which investigated whether icosapent ethyl resulted in a reduction of clinical outcomes in patients with COVID-19.

AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.

Is a therapeutic dose of heparin in COVID-19 patients more effective than standard dose heparin? Prof. ten Cate gives an update on the most recent findings.

In an open-label, multiplatform, randomized trial, therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin did not improve clinical outcomes compared to usual-care pharmacologic thromboprophylaxis in critically ill COVID-19 patients.

This study described the clinical features of 23 patients who after receiving the first dose of ChAdOx1 nCoV-19 vaccine developed atypical platelet factor 4 (PF4)-dependent thrombosis and/or thrombocytopenia that resembles heparin-induced thrombocytopenia.

Some cases of thrombotic events combined with thrombocytopenia have been described after COVID-19 vaccination with AZD1222. This thrombotic disorder clinically resembles heparin-induced thrombocytopenia, with a different serological profile.

ISC 2021 Using data of the AHA COVID-19 CVD Registry, risk of ischemic stroke was 0.75% in patients hospitalized with COVID-19, which is lower than previously reported.

Compared to the same period in 2019, cholesterol testing rate was almost 40% lower between March-September 2020 when analyzing data from a healthcare system in New England, USA.

The ACC has published a statement with key clinical risk considerations that offers guidance on the incorporation of CV risk into vaccine allocation prioritizing decisions.

Incidence of thrombotic complications remained high in hospitalized COVID-19 patients in the second wave. Thromboprophylaxis is therefore warranted in these patients.

Four leading CV organizations, the WHF, ACC, AHA and ESC, have published a joint statement as a call for action to reduce the impact of air pollution on people’s health.